The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is above average at 37.05x. The 36-month beta value for AZN is also noteworthy at 0.49. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for AZN is 3.10B, and at present, short sellers hold a 0.28% of that float. The average trading volume of AZN on April 29, 2024 was 6.36M shares.
AZN) stock’s latest price update
Astrazeneca plc ADR (NASDAQ: AZN) has seen a rise in its stock price by 0.19 in relation to its previous close of 75.03. However, the company has experienced a 9.66% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-27 that Since I covered AstraZeneca last October, shares have narrowly outperformed the S&P 500 index. Thanks to impressive results throughout the business, the company’s total revenue and core EPS jumped in the first quarter. AstraZeneca’s interest coverage ratio remains robust, and the dividend remains amply covered with free cash flow.
AZN’s Market Performance
Astrazeneca plc ADR (AZN) has seen a 9.66% rise in stock performance for the week, with a 10.12% gain in the past month and a 12.03% surge in the past quarter. The volatility ratio for the week is 1.40%, and the volatility levels for the past 30 days are at 1.29% for AZN. The simple moving average for the past 20 days is 9.27% for AZN’s stock, with a 12.60% simple moving average for the past 200 days.
Analysts’ Opinion of AZN
Morgan Stanley gave a rating of “Overweight” to AZN, setting the target price at $85 in the report published on January 23rd of the current year.
AZN Trading at 12.36% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.84% of loss for the given period.
Volatility was left at 1.29%, however, over the last 30 days, the volatility rate increased by 1.40%, as shares surge +10.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.91% upper at present.
During the last 5 trading sessions, AZN rose by +9.66%, which changed the moving average for the period of 200-days by +13.09% in comparison to the 20-day moving average, which settled at $69.16. In addition, Astrazeneca plc ADR saw 11.61% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.82 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.12. Equity return is now at value 17.29, with 6.36 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.36. The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is 5.13.
Currently, EBITDA for the company is 13.91 billion with net debt to EBITDA at 1.8. When we switch over and look at the enterprise to sales, we see a ratio of 5.58. The receivables turnover for the company is 3.38for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
In summary, Astrazeneca plc ADR (AZN) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
